|
- Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million . . .
Regeneron Pharmaceuticals on Monday announced it will acquire "substantially all" of 23andMe's assets for $256 million Stream NBC 5 for free, 24 7, wherever you are The drugmaker participated in
- Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for . . .
Regeneron intends to acquire 23andMe’s Personal Genome Service ® (PGS), Total Health and Research Services business lines, together with its Biobank and associated assets, for $256 million and for 23andMe to continue all consumer genome services uninterrupted Subject to bankruptcy court and regulatory approvals and other customary closing
- Drug company Regeneron to buy bankrupt 23andMe. What about your data?
Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19 for $256 million at
- Regeneron Pharmaceuticals to buy 23andMe for $256M
The acquisition of 23andMe will not include Lemonaid Health, a telemedicine service that 23andMe purchased for about $400 million in 2021 Regeneron pointed to its own genetic testing of some 3
- Biotech company Regeneron to buy bankrupt 23andMe for $256M
Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without interruption and uphold its privacy protection
- Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday Regeneron said it will comply with 23andMe’s
- Regeneron, A Leading U. S. Biotechnology Company, to Acquire 23andMe in . . .
SAN FRANCISCO, May 19, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered into a definitive agreement for the sale of 23andMe to Regeneron Pharmaceuticals, Inc (“Regeneron”) (NASDAQ: REGN), a leading U S
- Pharma giant Regeneron to buy 23andMe and its customers data for $256M . . .
Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction Regeneron said it will acquire 23andMe’s genomics
|
|
|